Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jul 14, 2021 10:57am
139 Views
Post# 33542145

RE:The “new strategy”

RE:The “new strategy”

My guess is that since the only 3 analysts that cover it do not focus on the pipeline as the huge value creator and instead still fret over quarterly revenues and EBITDA, they expect higher costs no an earnings miss off their ridiculously high expectations.  Since there's no valuation anchoring to the pipeline at this point (or a mild one if you assume the $1+ in option value for SORT1), the brokers are telling clients to expect dull quarter and they sell. 


If the analysts don't spend the time to understand what they could have in either oncology or NASH, their clients will be bailing a mere months before potential catalysts that will solidify a completely different picture than what they describe to their clients.  It's a shame they aren't actual biotech analysts that factor in the totality of evidence and potential.  Oh well, their loss, one hopes.   


Another reason they desperately need someone to put the whole picture together, someone that has the background to put all the pieces together and value the possibilities even with high discount rates for the risk, 


Bucknelly21 wrote: I think the new strategy is to engage the market less, in that case they are on fire...

 

<< Previous
Bullboard Posts
Next >>